Mar 29, 2018 Webinar

New Tufts Study: Assessing CRO Oversight Effectiveness and Impact

With increased attention to ICH E6(R2) guidance and on achieving higher levels of transparency and speed, many pharmaceutical companies have begun to implement new CRO oversight practices.

This webinar presents the results of a recent study conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD) that benchmarks CRO oversight practices and their impact and effectiveness.

Ken Getz of Tufts CSDD discusses the summary results of the study and their implications. Specific areas covered include:

  • CRO oversight models
  • Oversight challenges
  • Performance metrics for oversight effectiveness
  • Insights into new best practices
Watch this Webinar Now!
  • Watch this Webinar Now

  • You may unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.